Context Therapeutics Inc. (CNTX): Price and Financial Metrics

Context Therapeutics Inc. (CNTX): $1.63

0.02 (-1.21%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

D

Add CNTX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#187 of 332

in industry

CNTX Price/Volume Stats

Current price $1.63 52-week high $2.75
Prev. close $1.65 52-week low $0.77
Day low $1.51 Volume 129,000
Day high $1.67 Avg. volume 304,395
50-day MA $2.02 Dividend yield N/A
200-day MA $1.83 Market Cap 122.25M

CNTX Stock Price Chart Interactive Chart >


Context Therapeutics Inc. (CNTX) Company Bio


Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a selective potent antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as ovarian, uterine (endometrial), and breast cancers. The company also engages in developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. In addition, it is involved in the development of Sigma1, a cellular protein that regulates homeostasis, which is in clinical studies for the treatment of breast and prostate cancer. Context Therapeutics Inc. has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of CLDN6xCD3 bsAb. The company was founded in 2015 and is based in Philadelphia, Pennsylvania.


CNTX Latest News Stream


Event/Time News Detail
Loading, please wait...

CNTX Latest Social Stream


Loading social stream, please wait...

View Full CNTX Social Stream

CNTX Price Returns

1-mo -18.50%
3-mo -34.27%
6-mo -18.50%
1-year 91.63%
3-year -68.53%
5-year N/A
YTD 44.25%
2023 73.39%
2022 -75.50%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!